Skip to main navigation
Logo
  • Careers
  • Contact
  • Home
  • Products
    • Overview
    • DSUVIA
    • Nafamostat - Niyad™
    • Nafamostat – LTX-608
    • Prefilled Syringes
  • Partnering
  • Investors
    • Overview
    • News & Events
    • Stock Information
    • SEC Filings
    • Corporate Governance
    • Shareholder Services
  • Media
    • Overview
    • Press Releases
    • Publications
  • Military
  • Careers
  • Contact

Investors

Contents

News Releases

Keyword search

9/6/2023
AcelRx Pharmaceuticals to Participate in the H.C. Wainwright Annual Investment Conference
8/10/2023
AcelRx Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7/27/2023
AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023
7/21/2023
AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules
7/18/2023
AcelRx Pharmaceuticals Announces $10 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
5/10/2023
AcelRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
4/27/2023
AcelRx to Host First Quarter 2023 Financial Results Call and Webcast on May 10, 2023
4/5/2023
AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA® to Alora Pharmaceuticals
3/30/2023
AcelRx Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results and Provides Corporate Update
3/21/2023
AcelRx to Host Full Year and Fourth Quarter 2022 Financial Results Call and Webcast on March 30, 2023
  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
  • Print Page
  • RSS Feeds
  • Overview
  • News & Events
    • News Releases
    • Upcoming Events
    • Past Events
  • Stock Information
  • SEC Filings
  • Corporate Governance
  • Shareholder Services
  

© 2023 AcelRx Pharmaceuticals, Inc. All Rights Reserved.

Privacy Policy | Terms of Use | CA state requirements